> top > docs > PubMed:23461584 > annotations

PubMed:23461584 JSONTXT

Annnotations TAB JSON ListView MergeView

sentences

Id Subject Object Predicate Lexical cue
TextSentencer_T1 0-47 Sentence denotes RET inhibition: implications in cancer therapy.
TextSentencer_T2 48-61 Sentence denotes INTRODUCTION:
TextSentencer_T3 62-177 Sentence denotes The RET gene encodes a receptor tyrosine kinase essential for ontogenesis of the enteric nervous system and kidney.
TextSentencer_T4 178-358 Sentence denotes Following identification of RET, it was found that somatic rearrangements of this gene, conventionally designated as RET/PTC, are frequently present in papillary thyroid carcinoma.
TextSentencer_T5 359-533 Sentence denotes Subsequently, activating germ line point mutations of RET were identified as being responsible for the hereditary medullary thyroid carcinoma syndromes MEN2A, MEN2B and FMTC.
TextSentencer_T6 534-627 Sentence denotes RET rearrangements have recently been identified in a small fraction of lung adenocarcinomas.
TextSentencer_T7 628-641 Sentence denotes AREA COVERED:
TextSentencer_T8 642-874 Sentence denotes The authors review the current field concerning the RET gene and protein, its involvement in cancer and the preclinical and clinical studies which highlight its role as a potentially important therapeutic target for several cancers.
TextSentencer_T9 875-890 Sentence denotes EXPERT OPINION:
TextSentencer_T10 891-1037 Sentence denotes Many multitargeted inhibitors which crossreact with RET have been developed and investigated in clinical trials targeting many cancer indications.
TextSentencer_T11 1038-1173 Sentence denotes In particular, VEGFR/PDGFR inhibitors, widely explored as antiangiogenics, have been intensively studied in thyroid carcinoma patients.
TextSentencer_T12 1174-1384 Sentence denotes Notwithstanding the efficacy observed with such agents, their common clinical activity in thyroid carcinoma is of short duration and includes frequent and severe side effects, limiting their therapeutic action.
TextSentencer_T13 1385-1490 Sentence denotes These findings are discussed and the need for improved, more specific RET-targeting drugs is highlighted.
T1 0-47 Sentence denotes RET inhibition: implications in cancer therapy.
T2 48-61 Sentence denotes INTRODUCTION:
T3 62-177 Sentence denotes The RET gene encodes a receptor tyrosine kinase essential for ontogenesis of the enteric nervous system and kidney.
T4 178-358 Sentence denotes Following identification of RET, it was found that somatic rearrangements of this gene, conventionally designated as RET/PTC, are frequently present in papillary thyroid carcinoma.
T5 359-533 Sentence denotes Subsequently, activating germ line point mutations of RET were identified as being responsible for the hereditary medullary thyroid carcinoma syndromes MEN2A, MEN2B and FMTC.
T6 534-627 Sentence denotes RET rearrangements have recently been identified in a small fraction of lung adenocarcinomas.
T7 628-641 Sentence denotes AREA COVERED:
T8 642-874 Sentence denotes The authors review the current field concerning the RET gene and protein, its involvement in cancer and the preclinical and clinical studies which highlight its role as a potentially important therapeutic target for several cancers.
T9 875-890 Sentence denotes EXPERT OPINION:
T10 891-1037 Sentence denotes Many multitargeted inhibitors which crossreact with RET have been developed and investigated in clinical trials targeting many cancer indications.
T11 1038-1173 Sentence denotes In particular, VEGFR/PDGFR inhibitors, widely explored as antiangiogenics, have been intensively studied in thyroid carcinoma patients.
T12 1174-1384 Sentence denotes Notwithstanding the efficacy observed with such agents, their common clinical activity in thyroid carcinoma is of short duration and includes frequent and severe side effects, limiting their therapeutic action.
T13 1385-1490 Sentence denotes These findings are discussed and the need for improved, more specific RET-targeting drugs is highlighted.

DisGeNET

Id Subject Object Predicate Lexical cue
T0 0-3 gene:5979 denotes RET
T1 32-38 disease:C0006826 denotes cancer
T2 0-3 gene:5979 denotes RET
T3 32-38 disease:C1306459 denotes cancer
R1 T0 T1 associated_with RET,cancer
R2 T2 T3 associated_with RET,cancer

PubmedHPO

Id Subject Object Predicate Lexical cue
T1 330-357 HP_0002895 denotes papillary thyroid carcinoma
T2 340-357 HP_0002890 denotes thyroid carcinoma
T3 473-500 HP_0002865 denotes medullary thyroid carcinoma
T4 483-500 HP_0002890 denotes thyroid carcinoma
T5 606-626 HP_0030078 denotes lung adenocarcinomas

DisGeNET5_gene_disease

Id Subject Object Predicate Lexical cue
23461584-2#121#124#gene8030 299-302 gene8030 denotes PTC
23461584-2#121#124#gene2158 299-302 gene2158 denotes PTC
23461584-2#121#124#gene5727 299-302 gene5727 denotes PTC
23461584-2#121#124#gene5979 299-302 gene5979 denotes PTC
23461584-2#121#124#gene5726 299-302 gene5726 denotes PTC
23461584-2#28#31#gene5979 206-209 gene5979 denotes RET
23461584-2#152#179#diseaseC0238463 330-357 diseaseC0238463 denotes papillary thyroid carcinoma
23461584-2#152#179#diseaseC0238463 330-357 diseaseC0238463 denotes papillary thyroid carcinoma
23461584-3#54#57#gene5979 413-416 gene5979 denotes RET
23461584-3#152#157#gene5979 511-516 gene5979 denotes MEN2A
23461584-3#114#141#diseaseC0238462 473-500 diseaseC0238462 denotes medullary thyroid carcinoma
23461584-4#0#3#gene5979 534-537 gene5979 denotes RET
23461584-4#77#92#diseaseC0001418 611-626 diseaseC0001418 denotes adenocarcinomas
121#124#gene8030152#179#diseaseC0238463 23461584-2#121#124#gene8030 23461584-2#152#179#diseaseC0238463 associated_with PTC,papillary thyroid carcinoma
121#124#gene8030152#179#diseaseC0238463 23461584-2#121#124#gene8030 23461584-2#152#179#diseaseC0238463 associated_with PTC,papillary thyroid carcinoma
121#124#gene2158152#179#diseaseC0238463 23461584-2#121#124#gene2158 23461584-2#152#179#diseaseC0238463 associated_with PTC,papillary thyroid carcinoma
121#124#gene2158152#179#diseaseC0238463 23461584-2#121#124#gene2158 23461584-2#152#179#diseaseC0238463 associated_with PTC,papillary thyroid carcinoma
121#124#gene5727152#179#diseaseC0238463 23461584-2#121#124#gene5727 23461584-2#152#179#diseaseC0238463 associated_with PTC,papillary thyroid carcinoma
121#124#gene5727152#179#diseaseC0238463 23461584-2#121#124#gene5727 23461584-2#152#179#diseaseC0238463 associated_with PTC,papillary thyroid carcinoma
121#124#gene5979152#179#diseaseC0238463 23461584-2#121#124#gene5979 23461584-2#152#179#diseaseC0238463 associated_with PTC,papillary thyroid carcinoma
121#124#gene5979152#179#diseaseC0238463 23461584-2#121#124#gene5979 23461584-2#152#179#diseaseC0238463 associated_with PTC,papillary thyroid carcinoma
121#124#gene5726152#179#diseaseC0238463 23461584-2#121#124#gene5726 23461584-2#152#179#diseaseC0238463 associated_with PTC,papillary thyroid carcinoma
121#124#gene5726152#179#diseaseC0238463 23461584-2#121#124#gene5726 23461584-2#152#179#diseaseC0238463 associated_with PTC,papillary thyroid carcinoma
28#31#gene5979152#179#diseaseC0238463 23461584-2#28#31#gene5979 23461584-2#152#179#diseaseC0238463 associated_with RET,papillary thyroid carcinoma
28#31#gene5979152#179#diseaseC0238463 23461584-2#28#31#gene5979 23461584-2#152#179#diseaseC0238463 associated_with RET,papillary thyroid carcinoma
54#57#gene5979114#141#diseaseC0238462 23461584-3#54#57#gene5979 23461584-3#114#141#diseaseC0238462 associated_with RET,medullary thyroid carcinoma
152#157#gene5979114#141#diseaseC0238462 23461584-3#152#157#gene5979 23461584-3#114#141#diseaseC0238462 associated_with MEN2A,medullary thyroid carcinoma
0#3#gene597977#92#diseaseC0001418 23461584-4#0#3#gene5979 23461584-4#77#92#diseaseC0001418 associated_with RET,adenocarcinomas

DisGeNet-2017-sample

Id Subject Object Predicate Lexical cue
T520 299-302 gene:8030 denotes PTC
T521 330-357 disease:C0238463 denotes papillary thyroid carcinoma
R1 T520 T521 associated_with PTC,papillary thyroid carcinoma
R2 T520 T521 associated_with PTC,papillary thyroid carcinoma
R3 T520 T521 associated_with PTC,papillary thyroid carcinoma
R4 T520 T521 associated_with PTC,papillary thyroid carcinoma
R5 T520 T521 associated_with PTC,papillary thyroid carcinoma

UBERON-AE

Id Subject Object Predicate Lexical cue
PD-UBERON-AE-B_T1 143-165 http://purl.obolibrary.org/obo/UBERON_0002005 denotes enteric nervous system
PD-UBERON-AE-B_T2 151-165 http://purl.obolibrary.org/obo/UBERON_0001016 denotes nervous system
PD-UBERON-AE-B_T3 170-176 http://purl.obolibrary.org/obo/UBERON_0002113 denotes kidney
PD-UBERON-AE-B_T4 606-610 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung

performance-test

Id Subject Object Predicate Lexical cue
PD-UBERON-AE-B_T1 143-165 http://purl.obolibrary.org/obo/UBERON_0002005 denotes enteric nervous system
PD-UBERON-AE-B_T2 151-165 http://purl.obolibrary.org/obo/UBERON_0001016 denotes nervous system
PD-UBERON-AE-B_T3 170-176 http://purl.obolibrary.org/obo/UBERON_0002113 denotes kidney
PD-UBERON-AE-B_T4 606-610 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung